RJA
AUPH icon

Raymond James & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Raymond James & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$112K Sell
15,225
-475
-3% -$2.94K ﹤0.01% 3771
2024
Q2 		$89.6K Sell
15,700
-2,001
-11% -$10.5K ﹤0.01% 3742
2024
Q1 		$88.7K Sell
17,701
-400
-2% -$2.71K ﹤0.01% 3750
2023
Q4 		$163K Buy
18,101
+1,150
+7% +$9.47K ﹤0.01% 3559
2023
Q3 		$132K Buy
16,951
+4,651
+38% +$45.5K ﹤0.01% 3550
2023
Q2 		$119K Buy
12,300
+500
+4% +$5.19K ﹤0.01% 3593
2023
Q1 		$129K Buy
+11,800
New +$104K ﹤0.01% 3595
2022
Q2 		– Sell
-11,300
Closed -$140K – 4032
2022
Q1 		$140K Buy
+11,300
New +$175K ﹤0.01% 3758
2021
Q4 		– Sell
-12,600
Closed -$279K – 4139
2021
Q3 		$279K Sell
12,600
-15,390
-55% -$244K ﹤0.01% 3467
2021
Q2 		$363K Buy
+27,990
New +$357K ﹤0.01% 3296
2021
Q1 		– Sell
-10,750
Closed -$149K – 4001
2020
Q4 		$149K Buy
+10,750
New +$156K ﹤0.01% 3484
2020
Q2 		– Sell
-41,495
Closed -$602K – 3527
2020
Q1 		$602K Buy
41,495
+13,050
+46% +$230K ﹤0.01% 2295
2019
Q4 		$576K Buy
+28,445
New +$262K ﹤0.01% 2627
2017
Q3 		– Sell
-29,000
Closed -$178K – 3408
2017
Q2 		$178K Buy
+29,000
New +$195K ﹤0.01% 3017

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Raymond James & Associates's AUPH Position: Q3 2024 in Review

Raymond James & Associates reduced its Aurinia Pharmaceuticals (AUPH) stake by 3% in Q3 2024, selling an estimated $2.94K and leaving 15,225 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

Raymond James & Associates first reported a position in AUPH in Q2 2017 and has held it in 14 quarters since. The position peaked at $602K in Q1 2020. 183 funds tracked by Wall St. Rank hold AUPH as of Q3 2024.

  • Raymond James & Associates held 15,225 shares of Aurinia Pharmaceuticals worth $112K as of Q3 2024.
  • Raymond James & Associates sold 475 Aurinia Pharmaceuticals shares in Q3 2024, an estimated $2.94K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3771 holding.
  • Raymond James & Associates first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 14 quarters since.
  • Raymond James & Associates's Aurinia Pharmaceuticals position peaked at $602K in Q1 2020.
  • 183 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.